Loading...
OTCMIPSEY
Market cap9.38bUSD
Dec 23, Last price  
28.13USD
1D
3.10%
1Q
-8.83%
Jan 2017
55.56%
IPO
217.80%
Name

Ipsen SA

Chart & Performance

D1W1MN
OTCM:IPSEY chart
P/E
3.47
P/S
0.68
EPS
7.80
Div Yield, %
4.29%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
7.08%
Revenues
3.31b
+4.75%
723,990,000788,709,000861,676,000993,757,0001,038,112,0001,112,383,0001,170,298,0001,234,909,0001,277,405,0001,281,800,0001,332,400,0001,520,200,0001,671,100,0002,011,800,0002,348,400,0002,692,800,0002,686,200,0002,748,600,0003,156,400,0003,306,400,000
Net income
644m
-0.65%
83,001,000119,230,000144,006,000151,069,000147,669,000157,166,00095,678,000424,000-29,491,000152,540,000153,500,000189,900,000225,900,000272,300,000389,500,000-54,900,000548,000,000646,600,000648,600,000644,400,000
CFO
866m
-9.16%
86,235,000149,553,000327,635,000175,970,000203,409,000257,623,000253,909,000175,446,000144,218,000188,100,000245,800,000223,600,000317,800,000422,900,000570,900,000627,700,000771,300,000871,800,000953,200,000865,900,000
Dividend
May 31, 20240.35363 USD/sh
Earnings
Feb 06, 2025

Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
URL
https://www.ipsen.com/
IPO date
Dec 06, 2005
Employees
5,300
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,306,400
4.75%
3,156,400
14.84%
2,748,600
2.32%
Cost of revenue
2,325,400
2,012,200
1,779,300
Unusual Expense (Income)
NOPBT
981,000
1,144,200
969,300
NOPBT Margin
29.67%
36.25%
35.27%
Operating Taxes
136,200
112,300
158,300
Tax Rate
13.88%
9.81%
16.33%
NOPAT
844,800
1,031,900
811,000
Net income
644,400
-0.65%
648,600
0.31%
646,600
17.99%
Dividends
(99,600)
(99,300)
(82,900)
Dividend yield
1.11%
1.19%
1.24%
Proceeds from repurchase of equity
(39,500)
(11,300)
(36,700)
BB yield
0.44%
0.14%
0.55%
Debt
Debt current
36,400
104,600
123,700
Long-term debt
368,800
667,000
662,900
Deferred revenue
37,700
40,600
45,800
Other long-term liabilities
338,500
232,300
308,900
Net debt
(254,900)
(534,000)
(161,300)
Cash flow
Cash from operating activities
865,900
953,200
871,800
CAPEX
(116,200)
(252,900)
(417,900)
Cash from investing activities
(1,072,200)
(458,600)
(332,000)
Cash from financing activities
(458,400)
(146,000)
(400,300)
FCF
851,600
1,132,400
905,500
Balance
Cash
528,400
1,169,300
814,700
Long term investments
131,700
136,300
133,200
Excess cash
494,780
1,147,780
810,470
Stockholders' equity
3,812,900
3,970,200
3,385,100
Invested Capital
4,011,320
3,139,620
2,963,530
ROIC
23.63%
33.82%
28.24%
ROCE
20.73%
26.21%
25.01%
EV
Common stock shares outstanding
83,375
83,098
83,358
Price
107.90
7.36%
100.50
24.84%
80.50
18.56%
Market cap
8,996,185
7.72%
8,351,333
24.45%
6,710,353
18.43%
EV
8,743,885
7,816,733
6,551,553
EBITDA
1,068,900
1,480,700
1,215,700
EV/EBITDA
8.18
5.28
5.39
Interest
19,400
23,800
23,700
Interest/NOPBT
1.98%
2.08%
2.45%